Received: 4 June 2019
Accepted: 14 November 2019
First Online: 29 November 2019
Ethics approval and consent to participate
: Institutional review board approval was obtained, and the study adhered to the Declaration of Helsinki.
: Not required by IRB. This study is retrospective without use of any individual’s protected health information in this published work. Gaining consent would be unduly burdensome given the time period of the study and inability to contact patients who have left the practice.
: Authors do not have conflict of interest or relationships relevant to this research. Individual disclosures include: <i>S. Bulas, S. Lopper, D. Ash, T. Sa- No financial interests or relationships to disclose; A. Kaufman [Alcon, 1800 Contacts]; V. Miraldi Utz [Spark Therapeutics –Advisor, Springer-Textbook Royalties, Retrophin – Research]</i> M. Mehta [Carl Zeiss Meditech, jCyte – Research, Alimera, Allergan, Clearside, DORC – Consultant, Eyedaptic – Equity], <i>D. Lovell [Cincinnati Children’s Hospital Medical Center receives payment for the work of Dr. Daniel Lovell from Astra-Zeneca, Centocor, Amgen, Bristol Meyers Squibb, AbbVie, Pfizer, Roche, Novartis, UBC, Ablynx, Boehringer-Ingelheim, Janssen, Lilly, Medimmune; Dr. Lovell is a member of DSMBs for Forest Research Institute and NIH-NIAMS and speaker’s bureaus for Genentech and Bristol Meyers Squibb].</i>